Secondary Logo

Institutional members access full text with Ovid®

Methods to Assess Ocular Motor Dysfunction in Multiple Sclerosis

Sheehy, Christy K., MS, PhD; Beaudry-Richard, Alexandra; Bensinger, Ethan; Theis, Jacqueline, OD; Green, Ari J., MD, MCR

Section Editor(s): Costello, Fiona MD, FRCP(C)

doi: 10.1097/WNO.0000000000000734
Disease of the Year: Multiple Sclerosis

From the Section Editor: The JNO “Disease of the Year: Multiple Sclerosis” series concludes with a focus on cutting edge techniques used to qualitatively and quantitatively evaluate ocular motility abnormalities. In their article, “Methods to Assess Ocular Motor Dysfunction in Multiple Sclerosis,” Sheehy and colleagues expand on the earlier works published by Lee et al, and Nerrant et al, which provide an elegant overview of extra-ocular movement findings associated with brainstem disorders, and multiple sclerosis, respectively. The tools highlighted by Sheehy and colleagues add to our understanding of structure-function relationships in multiple sclerosis, and further expand the role of visual system models in multiple sclerosis research and clinical trials. In the series finale, “The International Multiple Sclerosis Visual System Consortium: Advancing Visual System Research in Multiple Sclerosis,” Balcer and colleagues chronicle the inception, development, and achievements of IMSVISUAL, a consortium created by clinicians and researchers committed to advancing the role of visual outcomes in the care of multiple sclerosis patients. The ingenuity and accomplishments of IMSVISUAL will serve to inspire other international collaborations, and further advance scientific discovery in the field of neuro-ophthalmology.

Background: Multiple sclerosis (MS) is an inflammatory disease of the central nervous system causing the immune-mediated demyelination of the brain, optic nerve, and spinal cord and resulting in ultimate axonal loss and permanent neurological disability. Ocular motor dysfunction is commonly observed in MS but can be frequently overlooked or underappreciated by nonspecialists. Therefore, detailed and quantitative assessment of eye movement function has significant potential for optimization of patient care, especially for clinicians interested in treating visual symptoms or tracking disease progression.

Methods: A brief history of eye tracking technology followed by a contextualized review of the methods that can be used to assess ocular motor dysfunction in MS—including a discussion of each method's strengths and limitations. We discuss the rationale for interest in this area and describe new tools capable of tracking eye movements as a possible means of monitoring disease.

Results/Conclusions: This overview should inform clinicians working with patients with MS of how ocular motor deficits can best be assessed and monitored in this population. It also provides a rationale for interest in this field with insights regarding which techniques should be used for studying which classes of eye movements and related dysfunction in the disease.

Department of Neurology (CKS, AB-R, JHS, AJG), University of California, San Francisco, San Francisco, California; School of Medicine (AB-R), University of Ottawa, Ottawa, Ontario, Canada; School of Optometry (EB, JT), University of California, Berkeley, Berkeley, California; Vision Science Graduate Group (EB), University of California, Berkeley, Berkeley, California; and Department of Ophthalmology (AJG), University of California, San Francisco, San Francisco, California

Address correspondence to Christy K. Sheehy, MS, PhD, UCSF Department of Neurology, 675 Nelson Rising Lane, San Francisco, CA 94158; E-mail:

C.K. Sheehy and A.J. Green hold intellectual property related to the TSLO and its methods. C.K. Sheehy has a financial interest in the TSLO technology (Founder and CEO of C. Light Technologies). E. Bensinger is a paid consultant for C. Light Technologies. A.J. Green has received research support from NMSS, HHMI, Hilton Foundation, Sherak Foundation, Fidelity Foundation and has served on the scientific advisory board for Bionure, as well as provided service as a consultant on the endpoint adjudication committee for Medimmune. He was previously a paid expert witness for Mylan Pharmaceuticals, Amneal Pharmaceuticals, received grant support from Novartis pharmaceuticals, and served as an advisor for Inception Sciences. J. Theis was a paid consultant for C. Light Technologies. The remaining author reports no conflicts of interest.

© 2018 by North American Neuro-Ophthalmology Society